Since the onset of the COVID-19 pandemic in January 2020, the United States has recorded more than 32 million cases and nearly 600,000 deaths from the disease. Patients with COVID-19 face varied risk for increasing severity of disease, with the chance of progression and mortality being higher in older patients and those with comorbidities.
As US case counts fall amid widespread distribution of vaccines, the FDA has granted Emergency Use Authorization (EUA) to a pair of monoclonal antibody therapies that prevent the need for hospitalization in high-risk outpatients who have COVID-19. To help clinicians understand these therapies and determine which patients might benefit from antibody therapy, Rockpointe and the Potomac Center for Medical Education along with the National Infusion Center Association a collaboration of fifteen State Medical Societies, and supported through an educational grant from Regeneron offer a live, virtual CME program series.
High-Risk Patients with COVID-19: Outpatient Management to Prevent Progression is an hour-long webinars for hospitals and health systems, the presentation designed specifically for primary care and emergency clinicians who are responsible for the outpatient management of patients with mild-to-moderate COVID-19. The program will review the most current management guidelines and information about the mechanism of action, efficacy and safety data, and patient eligibility for the monoclonal antibodies that have received EUA to treat outpatients with COVID-19. These agents include a cocktail consisting of casirivimab and imdevimab and a cocktail of bamlanivimab and etesevimab.
Dates and times (sessions will be added as they are scheduled):
5/27/2021 – 4:00 – 5:00 PM ET
5/28/2021 – 3:30 – 4:30 PM ET
6/1/2021 – 7:00 – 8:00 AM ET
6/1/2021 – 1:15 – 2:15 PM ET
6/2/2021 – 7:00 – 8:00 AM ET
6/3/2021 – 12:00 – 1:00 PM ET
6/3/2021 – 5:00 – 6:00 PM ET
6/5/2021 – 8:00 – 9:00 AM ET
6/9/2021 – 12:00 – 1:00 PM ET
6/9/2021 – 3:15 – 4:15 PM ET
6/11/2021 – 12:00 – 1:00 PM ET
6/17/2021 – 12:00 – 1:00 PM ET
6/18/2021 – 9:00 – 10:00 AM ET
6/21/2021 – 12:00 – 1:00 PM ET
6/25/2021 – 11:30 – 12:30 PM ET
6/29/2021 – 8:00 – 9:00 AM ET
7/13/2021 – 8:00 – 9:00 AM ET
7/15/2021 – 7:00 – 8:00 PM ET
7/16/2021 – 12:15 – 1:15 PM ET
7/21/2021 – 12:00 – 1:00 PM ET
7/28/2021 – 12:30 – 1:30 PM ET
8/5/2021 – 1:00 – 2:00 PM ET
8/19/2021 – 9:00 – 10:00 AM ET
9/9/2021 – 12:00 – 1:00 PM ET
At the program’s conclusion, participants should be able to:
- Integrate the most recent recommendations when developing management strategies for outpatients with COVID-19.
- Assess the mechanism of action and efficacy and safety data for monoclonal antibodies that have FDA Emergency Use Authorization for managing outpatient COVID-19.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education (PCME) and Rockpointe. PCME, which is accredited by the ACCME to provide continuing medical education for physicians, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.
There is no fee for this activity, which is conducted in collaboration with the National Infusion Center Association and is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. To receive credit, participants must register, view the live CME activity in its entirety, and then complete the post-test, with a score of 75% or better, and evaluation. The estimated time for completion of this activity is one hour. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.
Through effective continuing medical education, Rockpointe strives to improve and advance the quality of patient care. Its educational programs have been at the forefront of new issues in healthcare, such as managing challenges posed by COVID-19, addressing racial disparities in care, and combating the nation’s opioid crisis. Additional available courses for COVID-19 include Dermatology, Diabetes, Obesity, Prostate Cancer, Lung Cancer, and Asthma and Telemedicine.
As part of its commitment to quality, Rockpointe works to inform the continuing-education community of significant quality-improvement issues through news and analysis on Policy and Medicine. In addition, its popular Medical Education Exchange (MEDX) CME regional meetings include sessions on the basics of quality improvement and alternative payment models, as well as relevant and scientifically accurate sessions on numerous disease states. All sessions include links back to associated National Quality Priorities to reinforce the bigger picture and the triple aim of: 1) improving health and 2) lowering cost to 3) better the patient experience. At Rockpointe, education equals quality.
For more details and to register for High-Risk Patients with COVID-19: Outpatient Management to Prevent Progression, go to https://www.pathlms.com/rockpointe/courses/30716 or click here.